Ayala Pharmaceuticals Inc (fka ADXS)

[fbg0316]

I'm not buying back. I think ADXS is much riskier with a higher probably of failure now and/or lower probability investors will see much of a return for the following: 1) so far no one is interesting in partnering the company's late stage asset, AXAL 2) Amgen, the only paying partner decided the next gen platform was not worth further investment and 3) we are about to see the second reverse split in less than six years time, so the company failed to add any value over six years. That is the most transparent indication that neither imvesotes or pharmas think the tech is worth much.